How much did Verastem achieve in EBIT for the current year?
In the current year, Verastem has achieved an EBIT of -119.7 M USD.
Verastem EBIT 2024
Verastem EBIT
-119.7 M USD
Ticker
VSTM
ISIN
US92337C1045
WKN
A1JTPU
In 2024, Verastem's EBIT was -119.7 M USD, a 29.99% increase from the -92.08 M USD EBIT recorded in the previous year.
The Verastem EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | 44.52 |
| 2027e | -55.43 |
| 2026e | -105.14 |
| 2025e | -123.87 |
| 2024e | -119.7 |
| 2023 | -92.08 |
| 2022 | -72.94 |
| 2021 | -61.41 |
| 2020 | -44.76 |
| 2019 | -132.34 |
| 2018 | -94.78 |
| 2017 | -67.8 |
| 2016 | -37 |
| 2015 | -58.2 |
| 2014 | -53.61 |
| 2013 | -41.4 |
| 2012 | -32.23 |
| 2011 | -13.7 |
| 2010 | -0.78 |
Verastem Revenue, EBIT, Net Income US92337C1045 · A1JTPU
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Verastem, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Verastem from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Verastem’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Verastem. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Verastem’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Verastem’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Verastem’s growth potential.
Verastem Revenue, EBIT and net profit per share
| Date | Verastem Revenue | Verastem EBIT | Verastem Net Income |
|---|---|---|---|
| 2029e | 368.15 M undefined | 0 undefined | -67.72 M undefined |
| 2028e | 276.58 M undefined | 44.52 M undefined | -89.48 M undefined |
| 2027e | 147.26 M undefined | -55.43 M undefined | -94.81 M undefined |
| 2026e | 53.4 M undefined | -105.14 M undefined | -67.02 M undefined |
| 2025e | 14.85 M undefined | -123.87 M undefined | -96.2 M undefined |
| 2024e | 6.58 M undefined | -119.7 M undefined | -131.24 M undefined |
| 2023 | 0 undefined | -92.08 M undefined | -87.37 M undefined |
| 2022 | 2.6 M undefined | -72.94 M undefined | -73.81 M undefined |
| 2021 | 2.05 M undefined | -61.41 M undefined | -71.2 M undefined |
| 2020 | 88.52 M undefined | -44.76 M undefined | -67.73 M undefined |
| 2019 | 17.46 M undefined | -132.34 M undefined | -149.21 M undefined |
| 2018 | 26.72 M undefined | -94.78 M undefined | -72.43 M undefined |
| 2017 | 0 undefined | -67.8 M undefined | -67.8 M undefined |
| 2016 | 0 undefined | -37 M undefined | -36.44 M undefined |
| 2015 | 0 undefined | -58.2 M undefined | -57.87 M undefined |
| 2014 | 0 undefined | -53.61 M undefined | -53.37 M undefined |
| 2013 | 0 undefined | -41.4 M undefined | -41.2 M undefined |
| 2012 | 0 undefined | -32.23 M undefined | -31.99 M undefined |
| 2011 | 0 undefined | -13.7 M undefined | -13.72 M undefined |
| 2010 | 0 undefined | -780,000 undefined | -790,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2010 | 0 USD | -780,000 USD | -790,000 USD |
| 2011 | 0 USD | -13.7 M USD | -13.72 M USD |
| 2012 | 0 USD | -32.23 M USD | -31.99 M USD |
| 2013 | 0 USD | -41.4 M USD | -41.2 M USD |
| 2014 | 0 USD | -53.61 M USD | -53.37 M USD |
| 2015 | 0 USD | -58.2 M USD | -57.87 M USD |
| 2016 | 0 USD | -37 M USD | -36.44 M USD |
| 2017 | 0 USD | -67.8 M USD | -67.8 M USD |
| 2018 | 26.72 M USD | -94.78 M USD | -72.43 M USD |
| 2019 | 17.46 M USD | -132.34 M USD | -149.21 M USD |
| 2020 | 88.52 M USD | -44.76 M USD | -67.73 M USD |
| 2021 | 2.05 M USD | -61.41 M USD | -71.2 M USD |
| 2022 | 2.6 M USD | -72.94 M USD | -73.81 M USD |
| 2023 | 0 USD | -92.08 M USD | -87.37 M USD |
| 2024e | 6.58 M USD | -119.7 M USD | -131.24 M USD |
| 2025e | 14.85 M USD | -123.87 M USD | -96.2 M USD |
| 2026e | 53.4 M USD | -105.14 M USD | -67.02 M USD |
| 2027e | 147.26 M USD | -55.43 M USD | -94.81 M USD |
| 2028e | 276.58 M USD | 44.52 M USD | -89.48 M USD |
| 2029e | 368.15 M USD | 0 USD | -67.72 M USD |
Verastem stock margins US92337C1045 · A1JTPU
The Verastem margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Verastem. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Verastem.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Verastem's sales revenue. A higher gross margin percentage indicates that the Verastem retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Verastem's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Verastem's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Verastem's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Verastem. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Verastem's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Verastem Margin History
| Verastem Gross margin | Verastem Profit margin | Verastem EBIT margin | Verastem Profit margin |
|---|---|---|---|
| 2029e | 100 % | 0 % | -18.4 % |
| 2028e | 100 % | 16.1 % | -32.35 % |
| 2027e | 100 % | -37.64 % | -64.39 % |
| 2026e | 100 % | -196.89 % | -125.51 % |
| 2025e | 100 % | -834.26 % | -647.89 % |
| 2024e | 100 % | -1,819.42 % | -1,994.84 % |
| 2023 | 100 % | 0 % | 0 % |
| 2022 | 100 % | -2,805.38 % | -2,838.85 % |
| 2021 | 100 % | -2,995.61 % | -3,473.17 % |
| 2020 | 62.77 % | -50.56 % | -76.51 % |
| 2019 | 92.9 % | -757.96 % | -854.58 % |
| 2018 | 99.36 % | -354.72 % | -271.07 % |
| 2017 | 100 % | 0 % | 0 % |
| 2016 | 100 % | 0 % | 0 % |
| 2015 | 100 % | 0 % | 0 % |
| 2014 | 100 % | 0 % | 0 % |
| 2013 | 100 % | 0 % | 0 % |
| 2012 | 100 % | 0 % | 0 % |
| 2011 | 100 % | 0 % | 0 % |
| 2010 | 100 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2010 | 100 % | 0 % | 0 % |
| 2011 | 100 % | 0 % | 0 % |
| 2012 | 100 % | 0 % | 0 % |
| 2013 | 100 % | 0 % | 0 % |
| 2014 | 100 % | 0 % | 0 % |
| 2015 | 100 % | 0 % | 0 % |
| 2016 | 100 % | 0 % | 0 % |
| 2017 | 100 % | 0 % | 0 % |
| 2018 | 99.36 % | -354.72 % | -271.07 % |
| 2019 | 92.9 % | -757.96 % | -854.58 % |
| 2020 | 62.77 % | -50.56 % | -76.51 % |
| 2021 | 100 % | -2,995.61 % | -3,473.17 % |
| 2022 | 100 % | -2,805.38 % | -2,838.85 % |
| 2023 | 100 % | 0 % | 0 % |
| 2024e | 100 % | -1,819.42 % | -1,994.84 % |
| 2025e | 100 % | -834.26 % | -647.89 % |
| 2026e | 100 % | -196.89 % | -125.51 % |
| 2027e | 100 % | -37.64 % | -64.39 % |
| 2028e | 100 % | 16.1 % | -32.35 % |
| 2029e | 100 % | 0 % | -18.4 % |
Verastem Aktienanalyse
What does Verastem do?
Verastem Inc. is a biopharmaceutical company founded by Dr. Christoph Westphal in Cambridge, Massachusetts, in 2010. The company focuses on developing drugs for the treatment of cancer and other serious diseases using technologies based on small molecules and RNA interference. The company specializes in developing therapies for patients with particularly aggressive types of cancer, such as diffuse large B-cell lymphoma (DLBCL), mesothelial tumors, liver cancer, and pancreatic cancer. Verastem collaborates closely with leading academic research institutions and clinics around the world to test and validate the efficacy and safety of its therapies. Verastem's business model is based on identifying and developing drug candidates based on the needs of patients with serious diseases. The company uses patented screening technologies to identify compounds that selectively target specific cancer cells without harming healthy cells. These compounds are then tested in preclinical and clinical studies to demonstrate their efficacy and safety for use in humans. One of Verastem's main areas of focus is the development of drugs that target signaling pathways in cancer cells. The company has several drugs in its pipeline that aim to inhibit proteins that are central to the growth and survival of cancer cells. These include VS-6063, VS-5584, and VS-5095. VS-6063 is a small molecule that targets the inhibition of the Focal Adhesion Kinase (FAK) protein. FAK plays a key role in the development and progression of cancer by promoting the growth and movement of cancer cells. VS-6063 is currently being studied in clinical trials for the treatment of mesothelioma, pancreatic cancer, and other types of cancer. VS-5584 is a small molecule that targets the inhibition of the mammalian Target of Rapamycin (mTOR) protein. mTOR is an important regulator of cell growth and division that is overactive in many types of cancer. VS-5584 is currently being studied in clinical trials for the treatment of liver cancer and other types of cancer. VS-5095 is a small molecule that targets the inhibition of the Wnt protein, which plays a crucial role in regulating cell proliferation and differentiation. Wnt is also involved in the development of cancer as it can contribute to the transformation of normal cells into cancer cells. VS-5095 is currently in preclinical studies for the treatment of various types of cancer. Verastem also has a promising pipeline of RNA interference therapies that aim to inhibit the expression of specific genes in cancer cells. One such therapy currently in clinical testing, VS-6061, targets the inhibition of the KRAS gene, which is mutated in many types of cancer and can promote the survival and growth of cancer cells. Overall, Verastem aims to develop drugs that are better tailored to the individual needs of patients and help them fight their disease. With its innovative research approach and strong pipeline of drug candidates, the company has the potential to fundamentally change the way cancer is treated. Verastem ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Verastem's EBIT
Verastem's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Verastem's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Verastem's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Verastem’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Verastem stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Verastem.
How has the EBIT of Verastem developed in recent years?
The EBIT of Verastem has increased by 29.99% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Verastem?
The EBIT of Verastem is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Verastem pay?
Over the past 12 months, Verastem paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Verastem is expected to pay a dividend of 0 USD.
What is the dividend yield of Verastem?
The current dividend yield of Verastem is .
When does Verastem pay dividends?
Verastem pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Verastem?
Verastem paid dividends every year for the past 0 years.
What is the dividend of Verastem?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Verastem located?
Verastem is assigned to the 'Health' sector.
Wann musste ich die Aktien von Verastem kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Verastem from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did Verastem pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of Verastem in the year 2023?
In the year 2023, Verastem distributed 0 USD as dividends.
In which currency does Verastem pay out the dividend?
The dividends of Verastem are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Verastem
Our stock analysis for Verastem Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verastem Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
